Lexaria Bioscience Corp. LXRP Archives - Page 16 of 27

FridaySep 21, 2018 2:14 pm

QualityStocksNewsBreaks – Lexaria Bioscience Corp.’s (CSE: LXX) (OTCQX: LXRP) Innovative Platform Demonstrates Excellent Results in Delivery of APIs to the Brain

Lexaria Bioscience’s (CSE: LXX) (OTCQX: LXRP) innovative delivery platform, DehydraTECH™, has demonstrated excellent results in delivery of nicotine to the brain in a recent lab study. An article discussing this reads, “The new report confirmed first generation results of in vivo tests on live animals showing that DehydraTECH™ was able to deliver more active pharmaceutical ingredients (APIs) across the brain’s protective blood brain barrier, as reported in an article published by the CFN Media Group (http://ibn.fm/rqa7h). Because of certain similarities in physical structure between the nicotine molecule and several of the drugs used to treat diseases such as Huntington’s, Parkinson’s,…

WednesdaySep 19, 2018 11:56 am

Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Grows IP Portfolio with Three More Patents in Australia, Two Notices of Allowance in the US

LXRP receives three new Australian patents and two new notices of allowance from the U.S. patent office; the company expects to receive corresponding patents by year-end 2018 If issued in both Australia and the U.S., LXRP would then hold 12 issued patents within its first patent family, and it continues to pursue pending application claims in this patent family globally The company, which has filed more than 50 patent applications globally, out-licenses its technology that promotes healthier and faster ingestion methods and lower overall dosing Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP), which owns the patented DehydraTECH (trademarked) ingestion technology…

FridaySep 14, 2018 11:20 am

QualityStocksNewsBreaks – Lexaria Bioscience Corp.’s (CSE: LXX) (OTCQX: LXRP) DehydraTECH™ Leverages Need for Speed in Fast-Track Drug Delivery

Lexaria Bioscience (CSE: LXX) (OTCQB: LXRP) is leveraging the need for speed in the likes of Formula One racing with its innovative drug delivery platform. A recent article discussing the company’s DehydraTECH™ reads, “In recent in vivo tests, the technology delivered 203 nanograms per milliliter (ng/mL) of nicotine in 15 minutes, 70 percent more than the control. Such rapidity may rival smoking; particularly as new research (http://ibn.fm/cvW29) suggests that ‘nicotine takes much longer than previously thought to reach peak levels in the brains of cigarette smokers.’ For tobacco industry giants on the search for safer delivery methods than smoking, the DehydraTECH™…

ThursdaySep 13, 2018 11:17 am

Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Receives More Patent Grants and Notices of Allowance

Lexaria’s DehydraTECH™ drug delivery platform promotes healthier ingestion methods The company continues to leverage its technology in new areas Lexaria was recently granted new Australian patents and new notices of allowance Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) is a leader in enhancing the flavor, bouquet and gastro-intestinal delivery of edible cannabinoid consumer products. It has patents granted in the U.S. and Australia for applications of its DehydraTECH™ technology. Moreover, the company has many patents pending in over 40 nations. Lexaria Bioscience’s business strategy involves expanding the applicability of its technology within and beyond the cannabinoid sector. Recently upgraded to…

FridaySep 07, 2018 9:18 am

QualityStocksNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Announces Strategic Additions to Patent Portfolio

Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP), a drug delivery platform innovator, this morning announced strategic additions to its patent portfolio. Per the update, three new Australian patents were recently granted to Lexaria by the Australian Patent Office, bringing the company’s total number of issued patents to eight, including four in the U.S. and four in Australia. All eight patents are within Lexaria's first patent family, "Food and Beverage Compositions Infused With Lipophilic Active Agents and Methods of Use Thereof." Additionally, the company received two new Notices of Allowance from the U.S. Patent & Trademark Office for pending patent applications,…

WednesdaySep 05, 2018 1:52 pm

Lexaria Bioscience Corp.’s (CSE: LXX) (OTCQX: LXRP) DehydraTECH Delivers Nicotine to Brain Faster

Ability to cross blood brain barrier – now confirmed – is significant for possible treatment of central nervous system diseases LXRP may also be able to deliver micro nicotine doses, as per developing FDA policies LXRP completes formation of wholly owned subsidiary, Lexaria Nicotine Corp., to better commercialize opportunities The company is a technology disrupter and has applied for new U.S. patent on its delivery process; it plans to out-license and develop future products Lexaria Bioscience Corp.’s (CSE: LXX) (OTCQX: LXRP) patented DehydraTECH™ drug delivery platform has been confirmed in analysis of a second generation lab study on 40 rats…

FridayAug 31, 2018 12:32 pm

Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Offers Viable and Effective Alternatives for Nicotine Delivery

Results from second in vivo study of 2018 a success DehydraTECH™ had a 90.2 percent greater absorption rate in the first 10 minutes Clients are improving high-quality products through the enhancement of this drug delivery platform Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP), a company focused on developing and out-licensing its disruptive drug delivery platform DehydraTECH™, recently announced the results of its second in vivo study of 2018 evaluating this edible technology’s use as a nicotine delivery system (http://ibn.fm/s03xG). The study was carried out by a third-party laboratory, which discovered that the absorption of nicotine was significantly greater when delivered by…

ThursdayAug 30, 2018 9:43 am

QualityStocksNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Reports Additional Encouraging Results from DehydraTECH™ Nicotine Study

Lexaria Bioscience (CSE: LXX) (OTCQB: LXRP) this morning announced further results from its recently completed second-generation study in 40 rats in addition to the partial results released earlier this month. The in vivo study evaluated the ability of the company’s DehydraTECH™ technology to deliver nicotine as quickly as 2 minutes after oral administration. Lexaria’s technology delivered 90.2% more nicotine over the first 10 minutes of the study than the concentration-matched control formulation by the 10-minute mark. To better commercialize opportunities within the nicotine sector, the company has also completed the formation of a wholly-owned subsidiary, Lexaria Nicotine Corp. "Lexaria's DehydraTECH™…

FridayAug 24, 2018 12:36 pm

QualityStocksNewsBreaks – Lexaria Bioscience Corp.’s (CSE: LXX) (OTCQX: LXRP) Human Clinical Study Confirms Significant Delivery, Bioavailability Results

Lexaria Bioscience (CSE: LXX) (OTCQB: LXRP) is pleased with recent significant results from a new human clinical study to evaluate its DehydraTECH™ powered TurboCBD™ and cannabidiol (CBD) fortified hemp oil capsules (http://ibn.fm/rPBS5). An article discussing this reads, “Results corroborate and confirm earlier in vitro and in vivo studies that evaluated DehydraTECH’s platform and measured higher levels of drug delivery achieved quicker than controls with matching CBD amounts. LXRP said that it believes nearly identical bioavailability enhancement results would be shown if the cannabinoid was THC instead of CBD.” To view the full article, visit http://ibn.fm/yn12L About Lexaria Bioscience Corp. Lexaria…

ThursdayAug 23, 2018 10:02 am

Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Drug Delivery Platform Takes Dosage from Zero to 203 in 15 Minutes

DehydraTECH™ methodology offers safer alternative to smoking Possible nicotine delivery platform for Big Tobacco Several licensing agreements for technology already signed Formula One racing is not the only place to find speed. The drug delivery platform DehydraTECH™, developed by Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP), has proven that it’s just as fast. In recent in vivo tests, the technology delivered 203 nanograms per milliliter (ng/mL) of nicotine in 15 minutes, 70 percent more than the control. Such rapidity may rival smoking; particularly as new research (http://ibn.fm/cvW29) suggests that “nicotine takes much longer than previously thought to reach peak levels in…

Site Search

Company Search

Tag: Lexaria Bioscience Corp. LXRP